Nimorazole - Azanta
Alternative Names: NimoralLatest Information Update: 05 Jul 2023
Price :
$50 *
At a glance
- Originator Azanta
- Developer Azanta; Danish Head and Neck Cancer Group; European Organisation for Research and Treatment of Cancer; International Atomic Energy Agency; The Christie NHS Foundation Trust
- Class Antibacterials; Antineoplastics; Antiprotozoals; Morpholines; Nitroimidazoles; Radiation-sensitising agents; Radiosensitisers; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Head and neck cancer
Most Recent Events
- 02 Jun 2023 Efficacy and adverse events data from a phase III trial in Head and Neck cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 12 Oct 2021 Chemical structure information added
- 05 Oct 2021 Phase-III clinical trials in Head and neck cancer (Combination therapy) ongoing in Denmark (PO) (NCT02661152)